A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis (Phase 3 Trial)

To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).

Inclusion Criteria:

• Participants who have been diagnosed AD based on the Diagnostic Criteria for Atopic Dermatitis (Criteria of the Japanese Dermatological Association)
• Participants with a history of AD for at least 3 years
• Participants who have an affected area covering from 5% to 40% of their body surface area (excluding the scalp) at the screening and baseline examinations
• Participants with an IGA score of 2 or 3 at the screening and baseline examinations

Exclusion Criteria:

• Participants who experienced an acute exacerbation of AD or contact dermatitis within 28 days prior to the baseline examination
• Participants who have been treated with OPA-15406 ointment in the past